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demonstrating that mucosal exposure to
DF is able to induce IgE production in
naive mice and boost IgE production in
mice already sensitized through the skin.
This observation indicates that there is no
correlation between SLIT-induced im-
provement of AD skin inflammation and
IgE serum levels. Along this line, we have
previously shown that the development
of AD skin lesions was not influenced by
serum IgE levels, as MHC II/ mice,
lacking CD4þ T cells and therefore
unable to produce IgE, developed even
more severe AD skin lesions than wild-
type mice (Hennino et al., 2007).
In summary, we provide evidence
that SLIT is efficient in a mouse model
of AD, in which sensitized animals
display high numbers of allergen-spe-
cific T cells. Systematic studies on the
effectiveness of SLIT in patients with
AD are rare. Two clinical studies, one
in adults and one in children with
specific IgE to house dust mite, showed
that SLIT or subcutaneous immunother-
apy improved mild–moderate atopic
dermatitis (Werfel et al., 2006; Pajno
et al., 2007). DF SLIT treatment led to
decreased numbers of specific T cells,
increased production of IL-10, and
enhanced protection from DF-induced
skin inflammation upon challenge. We
therefore postulate that SLIT could be
considered as an attractive treatment
for AD in well-defined patients, without
polysensitization relying on the pres-
ence of antigen-specific T cells for a
defined Ag (i.e., Der f or Der p) in
peripheral blood or on positive atopy
patch test to the allergen (Nosbaum
et al., 2010).
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TO THE EDITOR
Psoriasis vulgaris is a chronic disease
that affects 1–3% of the population
(Chandran and Raychaudhuri, 2010).
In addition to skin and possible joint
involvement, recent evidence suggests
associations between psoriasis and
other systemic diseases (Gelfand et al.,
2006). The molecular characterization
of psoriatic skin samples has led to
a greater understanding of disease
pathogenesis and has been useful inAbbreviations: DEG, differentially expressed gene; FC, fold change; TNF-a, tumor necrosis factor-a
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identifying therapeutic targets (Jabbari
et al., 2011). Much of our knowledge of
the molecular contributors of this dis-
ease has come from data generated by
microarray experiments, which rely on
the hybridization of labeled RNA/
cDNA to arrays of single-stranded
DNA sequences that correspond to
genes to estimate relative expression
levels. However, microarray studies
harbor limitations including a high
background, the need for known tem-
plate sequences, and a relatively lim-
ited dynamic range. It is possible
that important genes in psoriasis are
expressed at levels below the level
of reliable detection by microarrays
(Suarez-Farinas et al., 2010). In con-
trast, deep RNA sequencing (RNA-seq)
is a methodology in which the RNA/
cDNA species within a sample are
sequenced. The obtained sequences
can be aligned to a reference genome,
and a count number for each gene can
be generated. RNA-seq may be used for
transcriptomic profiling that does not
suffer from the shortcomings mentioned
for microarrays.
In this study, RNA-seq was used to
identify differentially expressed genes
(DEGs) in lesional and nonlesional
psoriatic skin samples. To our knowl-
edge, this is the first description of the
use of this technology in primary human
tissue to describe an inflammatory der-
matologic disease. These data were
compared with published psoriasis trans-
criptomic studies, which, up to this
point, exclusively used microarray tech-
nologies. RNA-seq identified a substan-
tial number of previously unrecognized
DEGs in psoriatic skin. Uniquely identi-
fied DEGs were compared with a list of
genes known to be synergistically upre-
gulated in keratinocytes by the com-
bined action of IL-17 and tumor necrosis
factor-a, and our data further support the
significance of this molecular interaction
in the pathogenesis of psoriasis.
To define the transcriptomic profile
of psoriatic skin, three pairs of lesional
and nonlesional skin biopsy specimens
were taken from patients with untreated
moderate-to-severe plaque psoriasis.
Total RNA was extracted, processed
as described (Supplementary Materials
online, Materials and Methods), and
sequenced on an Illumina (San Diego,
CA) GA-IIx platform (see Supplementary
Materials online, Supplementary Table
S1 online for library sizes of RNA-seq
samples). In parallel, the same RNA
samples were similarly processed
and hybridized to Affymetrix Human
Genome U133A 2.0 arrays (Affymetrix,
Santa Clara, CA). The RNA-seq method
identified 2,629 DEGs (Figure 1a) using
cutoffs of fold change (FC) 41.5 and a
false discovery rate of o0.1. These
cutoff values were used because of the
small sample size (see Supplementary
Figure S1 online for Venn diagrams
with other cutoff values). In contrast to
the RNA-seq analysis, 569 DEGs were
identified by microarray analysis using
the same criteria, of which 46% were
identified by RNA-seq. We were inter-
ested in identifying what may account
for the difference between the two data
sets. We assessed estimated FC by the
level of expression of the genes (Figure
1b). Although the microarray analysis
yielded an expected pattern of higher
FC values at intermediate expression
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Figure 1. Identification of a large set of differentially expressed genes in psoriatic skin. (a) Venn diagram comparing differentially expressed genes
(DEGs) between lesional and non-lesional skin of psoriatic patients as assessed by RNA sequencing (RNA-seq) and microarray analysis using the samples
from the same set of patients. Indicated in the diagram are the numbers of upregulated and downregulated DEGs. (b) Boxplots (means, boxes
25–75%, ± whiskers 95%) of the absolute values of the log2 fold change (FC) among 10 quantiles of concentrations for RNA-seq (left panel) and
microarray analyses (right panel). (c) Scatterplot of the FC values for all genes as estimated by RNA-seq and microarray analyses. (d) Genes were grouped
on the basis of dot plot location (left panel) and assessed for mean expression as determined by microarray analysis (right panel).
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levels, the RNA-seq analysis exhibited
higher FC values at lower expression
levels. Comparison of the estimated FC
by RNA-seq and microarray analysis
yielded a correlation coefficient of
0.641 (Figure 1c), with RNA-seq data
exhibiting overall larger FC values.
Further examination revealed a popula-
tion of genes that exhibited FC values at
or near zero by microarray analysis but
exhibiting a wide range of FC values by
RNA-seq. Analysis of the subset of this
population of genes with absolute FC
42 by RNA-seq (Figure 1d, right panel,
red) exhibited relatively low overall
expression (Figure 1d, left panel, red).
These data indicate that those genes in
which the absolute FC was 42 by
RNA-seq, but not by microarray, were
mostly low-abundance transcripts that
occupy a range of concentrations in
which microarray technology is known
to underestimate FC. In total, these
analyses show that RNA-seq has the
capability of identifying higher FC val-
ues at lower mRNA expression levels
and identifies a larger set of DEGs when
compared with microarrays.
We then compared the RNA-seq
data with the data from four published
transcriptomic analyses, all of which
used Affymetrix microarrays (Bowcock
et al., 2001; Zhou et al., 2003; Gud-
jonsson et al., 2009; Suarez-Farinas
et al., 2010). These published studies
identified 2,684 DEGs from 116 pa-
tients. In contrast, our RNA-seq study,
based on only three patients, yielded a
similar number of DEGs, albeit with
less stringent cutoff criteria, given the
considerably smaller sample size (see
Supplementary Figure S1 online for
Venn diagrams with other cutoff val-
ues). We sought to confirm the differ-
ential gene expression among a set of
12 genes selected in an unbiased
manner that were detected by RNA-
seq but not by the published microarray
analyses by real-time RT-PCR (Figure
2b). Using a different set of samples
from 15 untreated, moderate-to-severe
psoriasis patients, we examined the
expression of the six upregulated genes
GPR110, SPRR2A, HEPHL1, CLEC3A,
CD274, and SPRR2E, and found all to
be significantly upregulated by RT-PCR
(P-values of 5.62 106, 1.17 106,
3.24108, 2.08103, 6.54 106,
and 6.25 107, respectively). We ex-
amined the expression of six down-
regulated genes and found DIRAS2 and
LRRC3B to be statistically significant (P-
values of 8.25 105, 1.57 103,
0.14, 0.25, 0.16, and 0.05 for DIRAS2,
LRRC3B, DBX2, KRT25, PERF15, and
DDX25, respectively). Spearman’s rank
correlation coefficient for the RT-PCR
and RNA-seq data of the 12 genes
selected was 0.88 (P¼0.00060) (Sup-
plementary Figure S2 online). These
data supported the fact that the results
of the RNA-seq analysis were largely
externally valid.
Chiricozzi et al. (2011) recently
reported a set of genes in keratinocytes
that exhibited synergistic upregulation
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Figure 2. RNA-seq identifies a novel set of DEGs in psoriasis skin lesions not otherwise identified in
prior published studies. (a) Venn diagram comparing differentially expressed genes (DEGs) identified by
RNA sequencing (RNA-seq) and those identified by published microarray studies. (b) Real-time RT-PCR
confirmation of six upregulated (upper panel) and six downregulated (lower panel) DEGs identified by
RNA-seq. Displayed are mean log2 fold change ±SEM, 15 paired lesional and control nonlesional
samples for each gene. (c) SPRR2B protein expression was detected in psoriatic nonlesional (left) and
lesional (right) skin sections by immunohistochemistry ( 100 magnification, three sets of paired samples
assessed, bar¼200 mm).
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when stimulated with IL-17 and tumor
necrosis factor-a. Out of 160 genes, 53
‘‘synergistic’’ genes were identified in
at least one of the aforementioned
published studies; our RNA-seq analy-
sis identified 14 additional upregulated
DEGs (Supplementary Table S2 online),
further emphasizing the contribution
of this immunological circuit in the
pathogenesis of psoriasis. One of these
genes was SPRR2B; staining for the
protein product of this gene confirmed
increased expression in psoriatic
lesional skin (Figure 2c), corroborating
differences at the protein level of a
gene identified uniquely by RNA-seq
that is potentially informative with
regard to active molecular pathways
in psoriasis.
The transcriptomic profiling of
psoriasis has led to an increased
understanding of disease pathogenesis.
Although microarray technologies
have been instrumental in this regard,
it is clear that these tools detect an
incomplete set of DEGs. RNA-seq can
be used to supplement these prior
technologies. Here, the use of RNA-
seq methods substantially increased
the number of psoriasis-related DEGs.
Furthermore, DEGs that were uniquely
identified by RNA-seq, but not in
other published microarray studies,
further supported the role of IL-17 and
tumor necrosis factor-a synergy in
psoriasis. Examination of one of these
factors at the protein level confirmed
that RNA-seq is a powerful tool that
can be used to identify molecular
factors present in psoriasis lesions, and
may be useful in the identification
of therapeutic targets that to our knowl-
edge have not been reported pre-
viously. Further studies are in progress
to determine the biological signifi-
cance of DEGs uniquely discovered by
RNA-seq.
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TO THE EDITOR
Bullous pemphigoid (BP) is a sub-
epidermal blistering skin disease char-
acterized by an autoimmune response
to BP180 and BP 230, both of which
are hemidesmosomal proteins in the
basement membrane zone. Pathogenic
mechanisms of BP include complement
activation, recruitment of mast cells,
neutrophils, and eosinophils, liberation
of proteolytic enzymes, and direct
interference with the adhesion function
of BP180 (Kasperkiewicz and Zillikens,
2007; Iwata et al., 2009).
CC chemokine ligand (CCL)24 and
CCL26 are ligands for CC chemokine
receptor (CCR)3, which is expressed on
eosinophils and mast cells (Romagnani
et al., 1999). We have previously repor-
ted that serum levels of CCL26, but
not CCL24, significantly elevate in
patients with atopic dermatitis, and that
serum CCL26 levels are correlated withAbbreviations: BP, bullous pemphigoid; CCL, CC chemokine ligand; CCR, CC chemokine receptor
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